What is the enterprise value (EV) for Curis, Inc. (CRIS)?

The enterprise value (EV) for CRIS stock is $-2.33M.

Curis (CRIS) Enterprise Value: History & Chart

Compare

Curis, Inc.(CRIS)

Biotechnology · Lexington, MA

$0.79-0.01 (-1.79%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

Compare

About Curis, Inc.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Lexington, MA

22 employees

www.curis.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: James Dentzer

View full financials

NAME	MARKET CAP	ENTERPRISE VALUE (EV)
Curis, Inc. (CRIS)	$1.54M	$-2.33M
PMGC Holdings Inc. (ELAB)vs ›	$1.49M	N/A
Genprex, Inc. (GNPX)vs ›	$1.37M	N/A
Artelo Biosciences, Inc. (ARTL)vs ›	$1.36M	N/A
IM Cannabis Corp. (IMCC)vs ›	$1.17M	$9.70M
Autonomix Medical, Inc. (AMIX)vs ›	$1.92M	N/A
Cellyan Biotechnology Co., Ltd (HKPD)vs ›	$1.14M	$2.17M
Clearmind Medicine Inc. (CMND)vs ›	$1.11M	N/A
Aspire Biopharma Holdings, Inc. (ASBP)vs ›	$1.02M	N/A
Decoy Therapeutics Inc. (DCOY)vs ›	$888387.00	N/A

NAME

MARKET CAP

ENTERPRISE VALUE (EV)

Curis, Inc. (CRIS)

$1.54M

$-2.33M

PMGC Holdings Inc. (ELAB)vs ›

$1.49M

N/A

Genprex, Inc. (GNPX)vs ›

$1.37M

N/A